5-Hydroxymethyltubercidin exhibits potent antiviral activity against flaviviruses and coronaviruses, including SARS-CoV-2

Flavivirus Coronavirus

Entry

Release of viral RNA

Transcription of viral RNA by RdRp

Incorporation of HMTU-TP into viral RNA strand

Premature termination of viral RNA replication

Translation of viral proteins

Translation of viral RNA

RdRp

Highlights
We identified tubercidin derivatives as broad-spectrum antiviral compounds

HMTU exhibited potent antiviral activity against flaviviruses and coronaviruses

HMTU specifically inhibited replication at a late stage of the viral infection process

HMTU 5'-triphosphate inhibited RNA extension catalyzed by viral RdRp

Kentaro Uemura, Haruaki Nobori, Akihiko Sato, ..., Hirofumi Sawa, Akira Matsuda, Katsumi Maenaka

akahiko.sato@shionogi.co.jp (A.S.)
matsuda@pharm.hokudai.ac.jp (A.M.)
maenaka@pharm.hokudai.ac.jp (K.M.)
5-Hydroxymethyltubercidin exhibits potent antiviral activity against flaviviruses and coronaviruses, including SARS-CoV-2

Kentaro Uemura,1,2,3 Haruaki Nobori,1 Akihiko Sato,1,2,12,* Takao Sanaki,1,2 Shinsuke Toba,1,2 Michihito Sasaki,2 Akiho Murai,4 Noriko Saito-Tarashima,3 Noriaki Minakawa,4 Yasuko Orba,2,5 Hiroaki Kariwa,6 William W. Hall,5,7,8 Hirofumi Sawa,2,5,8,9 Akira Matsuda,10,11 and Katsumi Maenaka3,10,11,*

SUMMARY

Newly emerging or re-emerging viral infections continue to cause significant morbidity and mortality every year worldwide, resulting in serious effects on both health and the global economy. Despite significant drug discovery research against dengue viruses (DENVs) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), no fully effective and specific drugs directed against these viruses have been discovered. Here, we examined the anti-DENV activity of tubercidin derivatives from a compound library from Hokkaido University and demonstrated that 5-hydroxymethyltubercidin (HMTU, HUP1108) possessed both potent anti-flavivirus and anti-coronavirus activities at submicromolar levels without significant cytotoxicity. Furthermore, HMTU inhibited viral RNA replication and specifically inhibited replication at the late stages of the SARS-CoV-2 infection process. Finally, we demonstrated that HMTU 5’-triphosphate inhibited RNA extension catalyzed by the viral RNA-dependent RNA polymerase. Our findings suggest that HMTU has the potential of serving as a lead compound for the development of a broad spectrum of antiviral agents, including SARS-CoV-2.

INTRODUCTION

Newly emerging and re-emerging viral infectious diseases have been found to have a significant negative impact on global human health and global economies. Despite significant progress in medical treatment and the pharmacological sciences, these viral infections continue to cause millions of cases of disease and deaths worldwide annually.

Since the first reported case in December 2019, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has rapidly spread from person to person, and SARS-CoV-2 infection is now pandemic. The severe pneumonia-like disease caused by SARS-CoV-2, designated as coronavirus disease 2019 (COVID-19), has been linked to more than 191 million confirmed cases and 4.1 million deaths in 192 countries/regions [https://coronavirus.jhu.edu/map.html]. SARS-CoV-2 is a member of the Betacoronavirus genus of the family Coronaviridae, which consists of several types of human coronaviruses (HCoVs), including HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV).

Coronaviruses are enveloped, approximately 30 kb positive-sense, single-stranded RNA viruses that can infect a wide range of animal species, in addition to humans (Cui et al., 2019). To date, many compound-repurposing studies against SARS-CoV-2 have been performed (Ohashi et al., 2021; Riva et al., 2020; Wang et al., 2020), and several candidate compounds, including remdesivir, have been evaluated in clinical trials for the treatment of patients with COVID-19 (Grein et al., 2020; Li and De Clercq, 2020). However, there are as yet no fully effective specific drugs directed against SARS-CoV-2, and as such, effective therapeutic agents and vaccines against this virus are urgently needed.

Dengue virus (DENV) causes widespread endemic disease known as dengue fever and dengue hemorrhagic fever, resulting in an estimated 390 million total infections, 100 million clinical cases, and 500,000 severe
cases per year worldwide (Pierson and Diamond, 2020). DENV is made up of four serotypes, DENV1-4, which are members of the *Flavivirus* genus of the family *Flaviviridae*. This family includes several other significant human pathogens, such as Zika virus (ZIKV), yellow fever virus (YFV), Japanese encephalitis virus (JEV), and West Nile virus (WNV) (Pierson and Diamond, 2020). Flaviviruses are also enveloped and have an approximate 11 kb positive-sense, single-stranded RNA that can be transmitted between arthropods and humans (Simmonds et al., 2017; Vasilakis and Weaver, 2017). Dengue is defined as a neglected tropical disease (NTD) by the World Health Organization (Mackey and Liang, 2012), and there are yet no fully effective drugs or vaccines for treatment or prevention. Furthermore, there are as yet currently no specific agents that are fully effective against the other flaviviruses. As such, effective therapeutic agents and vaccines against all flaviviruses are also urgently needed.

Nucleos(t)ides and their analogs are widely reported to exhibit antiviral activities; thus, we have now examined the anti-DENV activity of an original nucleoside analog library from the Center for Research and Education on Drug Discovery of Hokkaido University in Japan. Tubercidin (7-deazaadenosine) showed anti-DENV activity. Tubercidin was identified as an antibiotic obtained from the bacteria *Streptomyces tubercidicus* (Suzuki and Marumo, 1960), and this compound with its derivatives has been reported to exhibit antiviral activity against several viruses including vesicular stomatitis virus (VSV), coxsackie virus, polio virus, rhinovirus, and ZIKV (Bergstrom et al., 1984; De Clercq et al., 1986; Eyer et al., 2016). In addition, recently, the antiviral activities of 5-substituted tubercidin derivatives against emerging RNA viruses have been reported (Milisavljevic et al., 2021). In this study, we further examined the antiviral activity of tubercidin derivatives and have demonstrated that 5-hydroxymethyltubercidin (HMTU, HUP1108) possessed potent anti-flavivirus and anti-coronavirus activities without obvious cytotoxicity. Furthermore, we examined the specific antiviral activity of HMTU against SARS-CoV-2 and SARS-CoV. We also performed real-time quantitative reverse transcription PCR (qRT-PCR) analysis, a 50% tissue culture infective dose

---

**Figure 1. Chemical structures of tubercidin and tubercidin derivatives**

(A) General structure of tubercidin.

(B) Chemical structure of tubercidin (HUP1136).

(C) Chemical structure of 5-hydroxymethyltubercidin (HUP1108, HMTU).

(D) Chemical structure of 5-formyltubercidin oxime (HUP1069).

(E) Chemical structure of 3-tubercidin N-oxide (HUP1077).
(TCID<sub>50</sub>) assay, immunofluorescence assays (IFAs), and the time-of-addition assay to better understand how HMTU affects the replication cycles of these viruses. Finally, we performed RNA extension assays using the viral RNA-dependent RNA polymerase (RdRp) which revealed the incorporation of HMTU 5′-triphosphate (HMTU-TP) into viral RNA, resulting in chain termination of the viral RNA.

**RESULTS**

**Antiviral activities of tubercidin derivatives on flaviviruses and human coronaviruses**

In this study, we initially screened 753 nucleoside analogs in a compound library from Hokkaido University. The half maximal effective concentration (EC<sub>50</sub>) and half maximal cytotoxic concentration (CC<sub>50</sub>) values of these compounds were initially determined using DENV2 in BHK-21 cells. From the results of the 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay (Nobori et al., 2018), we selected four tubercidin derivatives with potent anti-DENV2 activity for further studies (Figure 1A; Table 1): HUP1136 (tubercidin, EC<sub>50</sub> < 0.125 μM, Figure 1B), HUP1108 (HMTU, EC<sub>50</sub> =0.24 μM, Figure 1C), HUP1069 (5-formyltuberucidin oxime, EC<sub>50</sub> < 0.125 μM, Figure 1D), and HUP1077 (3-tubercidin N-oxide, EC<sub>50</sub> =0.95 μM, Figure 1E). Furthermore, cytotoxicity assays were performed at the same time to determine the toxicity of these compounds. Although HUP1136 and HUP1069 showed high cytotoxicity, HUP1108 and HUP1077 did not exhibit cytotoxicity against BHK-21 cells at concentrations up to 20 μM (Table 1). Subsequently, we evaluated the antiviral activities of HUP1108 against other flaviviruses (ZIKV, YFV, JEV, and WNV), and HUP1108 was shown to inhibit all of these flaviviruses, as shown in Table 2. The results suggested that tubercidin and tubercidin derivatives are potentially broad-spectrum antiviral agents, and these findings are consistent with those described in previous reports (Eyer et al., 2016; Milisavljevic et al., 2021; Olsen et al., 2004).

In view of the circumstances underlying the COVID-19 pandemic, we rescreened nine tubercidin derivatives, including the above four named compounds against human coronaviruses using the resazurin reduction assay (Sanaki et al., 2019). We also examined whether these tubercidin derivatives inhibited SARS-CoV-2 replication using real-time qRT-PCR analysis. In the resazurin reduction assay using MRC5 cells, HUP1136, HUP1108, HUP1069, and HUP1077 exhibited strong antiviral activities against both HCoV-OC43 and HCoV-229E, whereas no or only low anti-HCoV activities of other tubercidin derivatives

### Table 1. EC<sub>50</sub> and CC<sub>50</sub> values of tubercidin derivatives in DENV2-infected BHK-21 cells

| Compound ID | R<sup>1</sup> | R<sup>2</sup> | DENV2 EC<sub>50</sub> (μM) | CC<sub>50</sub> (μM) |
|-------------|--------------|--------------|----------------|-----------------|
| HUP1136     | H            | H            | <0.125         | 0.34            |
| HUP1108     | CH<sub>2</sub>OH | H            | 0.24           | >20             |
| HUP1069     | CH=NOH       | H            | <0.125         | 0.18            |
| HUP1077     | H            | H            | 0.95           | >20             |
| Ribavirin   |              |              | 28             | >400            |

### Table 2. EC<sub>50</sub> Values of HUP1108 (HMTU) against flaviviruses

| Virus | Cell line | Time | Assay | HUP1108 EC<sub>50</sub> (μM) | Ribavirin EC<sub>50</sub> (μM) | Favipiravir EC<sub>50</sub> (μM) |
|-------|-----------|------|-------|-----------------|-----------------|-----------------|
| DENV1 | BHK-21    | 5 days | Resazurin | 0.35 | 62 | 17 |
| DENV2 | BHK-21    | 4 days | Resazurin | 0.24 | 19 | 4.4 |
| DENV3 | BHK-21    | 5 days | Resazurin | 0.42 | 54 | 13 |
| DENV4 | BHK-21    | 5 days | Resazurin | 0.52 | 86 | 5.2 |
| ZIKV  | BHK-21    | 3 days | MTT     | 1.3  | 31  | 40 |
| YFV   | BHK-21    | 3 days | MTT     | 0.27 | 34  | 57 |
| JEV   | BHK-21    | 3 days | MTT     | 0.50 | 33  | 80 |
| WNV   | BHK-21    | 3 days | MTT     | 0.95 | 52  | >100 |
were observed (Table 3). In the qRT-PCR analysis using Caco-2 cells, HUP1136 (EC90 = 0.087 μM), HUP1108 (EC90 = 0.57 μM), HUP1069 (EC90 = 0.20 μM), and HUP1077 (EC90 = 3.5 μM) inhibited SARS-CoV-2 infection (Table 3). As noted above, HUP1136 and HUP1069 showed high cytotoxicity in MRC5 cells. Furthermore, the antiviral activities of HUP1077 were lower than those of the other three compounds. Thus, we selected HUP1108 (HMTU) for further analysis of activity against human coronaviruses.

**HMTU inhibits HCoV replication**

To evaluate the effects of HMTU on HCoV infections, we performed a resazurin reduction assay using MRC5 cells and compared the anti-coronaviral effect of HMTU with that of a Food and Drug Administration (FDA)-approved drug, remdesivir. The results showed that the EC50 of HMTU against HCoV-OC43 and HCoV-229E was 0.378 ± 0.023 and 0.528 ± 0.029 μM, respectively (Table 4). Importantly, the CC50 of HMTU obtained from the MRC5 cells was >50 μM, whereas the selectivity index (SI = CC50/EC50) for this assay system was >132 for HCoV-OC43 and >94 for HCoV-229E. The EC50 of remdesivir against HCoV-OC43 and HCoV-229E was 0.229 ± 0.022 and 0.071 ± 0.005 μM, respectively, which was consistent with a previous report (Brown et al., 2019). To examine the mechanism of HMTU antiviral activity, qRT-PCR analysis measuring both subgenomic (nucleocapsid) and genomic (ORF1b) viral RNA transcripts, a TCID50 assay to measure the progeny virus titer, and IFA for the detection of the viral nucleoprotein were performed. qRT-PCR analysis revealed a dose-dependent inhibition of HMTU against HCoV-OC43 (Figure 2A) and HCoV-229E (Figure 2C) replication for both subgenomic (Figures 2A and 2C; blue bars) and genomic (Figures 2A and 2C; red bars) RNA transcripts. The TCID50 assay also revealed more than a 1-log reduction in progeny virus titer supernatants of HCoV-OC43-infected Huh7 cells (Figure 2B; dark gray bar) or A549/TMPRSS2 cells (Figure 2B; light gray bar) treated with 1 μM HMTU. Furthermore, IFA demonstrated that positive signals of viral nucleoprotein were also decreased

### Table 3. EC50 and CC50 values of tubercidin derivatives in HCoV-infected MRC5 cells and EC90 values against SARS-CoV-2

| Compound ID | R1 | R2 | HCoV-OC43 EC50 (μM) | HCoV-229E EC50 (μM) | SARS-CoV-2 EC90 (μM) |
|-------------|----|----|---------------------|---------------------|----------------------|
| HUP1136     | H  | H  | 0.11                | <0.078              | 0.66                 |
| HUP1108     | CH2OH | H | 0.35                | 0.43                | >50                  |
| HUP1069     | CH=NNOH | H | 0.055               | <0.078              | 0.74                 |
| HUP1077     | H  | N3-O  | 4.3                 | 4.0                 | >20                  |
| HUP1078     | NO2 | H  | >10                 | 2.0                 | 0.33                 |
| HUP1079     | CH3 | H  | >10                 | >10                 | >50                  |
| HUP1109     | CN | H  | >10                 | 2.3                 | 0.59                 |
| HUP1111     | H  | CN | >10                 | >10                 | >50                  |
| HUP1070     | 1-Morpholinomethyl | Br | >10                 | >10                 | ND                   |

aResazurin reduction assay using MRC5 cells.

bCytotoxicity against MRC5 cells.
cqRT-PCR analysis using Caco-2 cells.
dND indicates not determined.

### Table 4. EC50 and CC50 values of HMTU and remdesivir in HCoV-infected MRC5 cells

| Compound   | HCoV-OC43 EC50 (μM) | HCoV-229E EC50 (μM) | MRC5 CC50 (μM) | Huh7 CC50 (μM) | A549/TMPRSS2 CC50 (μM) | VeroE6/TMPRSS2 CC50 (μM) | Caco-2 CC50 (μM) |
|------------|---------------------|---------------------|----------------|---------------|------------------------|--------------------------|------------------|
| HMTU       | 0.378 ± 0.023       | 0.528 ± 0.029       | >50            | >20           | >20                    | >20                      | >20              |
| Remdesivir | 0.229 ± 0.022       | 0.071 ± 0.005       | >50            | >20           | >20                    | >20                      | >20              |

Each value represents as the mean ± SEM from three independent experiments.
Figure 2. Antiviral activities of HMTU against HCoVs in vitro

(A and C) Viral RNA expression was quantified by qRT-PCR analysis. Huh7 cells were infected with HCoV-OC43 (A) or HCoV-229E (C) at a multiplicity of infection (MOI) of 0.1 or 0.05, respectively, containing a serially diluted compound. At 48 hpi, total RNA was collected, and the relative expression of the Nucleocapsid and ORF1b genes was measured. Significant differences were observed compared to the non-treated control.

(B) Log TCID<sub>50</sub>/mL of Huh7 and A549/TMPRSS2 cells infected with HCoV-OC43. The virus load was reduced in a dose-dependent manner with HMTU treatment.

(D) Fluorescent microscopy images showing HCoV-OC43 infected cells treated with different concentrations of HMTU.
HMTU effectively inhibits both SARS-CoV and SARS-CoV-2 replication

Subsequently, we examined the antiviral activity of HMTU against both SARS-CoV and SARS-CoV-2 using qRT-PCR analysis measuring both subgenomic (nucleocapsid) and genomic (RdRp) viral RNA transcripts, TCID<sub>50</sub> assays measuring progeny virus titer, and IFA for the detection of the viral spike protein. SARS-CoV (Figure 3A) and SARS-CoV-2 (Figure 3C) RNA replication was inhibited in a dose-dependent manner in both subgenomic (Figures 3A and 3C; blue bars) and genomic (Figures 3A and 3C; red bars) RNA transcripts. Progeny virus titers were reduced by more than 1-log TCID<sub>50</sub>/mL in supernatants of SARS-CoV and SARS-CoV-2-infected cells in the presence of 0.5 mM HMTU (Figures 3B and 3D). Furthermore, inhibition of the viral spike protein expression was dose dependently observed with HMTU. In addition, viral protein expression was significantly inhibited in both SARS-CoV and SARS-CoV-2 in the presence of 1 mM HMTU (Figure 3E). These results suggest that HMTU inhibits the replication of SARS-CoV and SARS-CoV-2 and has a potential for treatment of both viruses.

HMTU inhibits the post-entry step of the SARS-CoV-2 infection cycle

Subsequently, we performed a time-of-addition assay following the methods previously described by Wang et al. (Ohashi et al., 2021; Wang et al., 2020). In this assay, Caco-2 cells were treated with 1 mM HMTU at three steps in the SARS-CoV-2 infection cycle (whole, entry, and post-entry) as described in the Methods section, and viral replication was then measured by both qRT-PCR analysis targeting the viral nucleocapsid region and the previously described TCID<sub>50</sub> assay. qRT-PCR analysis demonstrated that HMTU significantly reduced intracellular and extracellular viral RNAs at the post-entry step but not at the entry step in SARS-CoV-2-infected cells (Figures 4A–4C). These data demonstrated that HMTU contributed to the inhibition of SARS-CoV-2 at a late stage of virus replication.

HMTU 5′-triphosphate inhibits RNA extension by viral RdRp

Nucleoside analogs are known to inhibit viral RNA synthesis or disrupt viral RNA function. We hypothesized that HMTU-TP could be incorporated into newly synthesized viral RNA by viral RdRp and as a result inhibit viral RNA synthesis. To determine if HMTU-TP is incorporated into the RNA template by viral RdRp, resulting in chain termination, we performed the primer extension assays as previously described by Lu et al. (Lu et al., 2017).

Recombinant ZIKV NS5 protein was incubated with the RNA primer/template (RNA P/T) in the presence of adenosine triphosphate analog [ATP, 3′-deoxyATP (3′-dATP), or HMTU-TP]. Then, reactions were initiated by addition of four natural ribonucleotides (ATP, GTP, CTP, and UTP). As a positive control for chain termination, 3′-dATP was used. As expected, ATP was incorporated into RNA template and caused extension of the template. Incorporation of 3′-dATP prevented RNA extension in the presence of the next correct ribonucleotides (Figure 5A). HMTU-TP was also incorporated into RNA template, resulting in chain termination by ZIKV RdRp (Figures 5A and 5B). These results suggested that HMTU inhibits viral RdRp and synthesis of viral RNA by chain termination.

DISCUSSION

Many drug-repurposing studies that target SARS-CoV-2 have been carried out, and several candidates and/or urgently approved agents have been employed (Grein et al., 2020; Li and De Clercq, 2020; Ohashi et al., 2021; Wang et al., 2020). Thus, these results suggest that HMTU possesses specific antiviral activity against HCoV replication.
Tubercidin (7-deazaadenosine) and tubercidin derivatives have been reported to exhibit antiviral activities against several viruses such as VSV, coxsackie virus, polio virus, rhinovirus, and ZIKV (Bergstrom et al., 1984; De Clercq et al., 1986; Eyer et al., 2016). Alternatively, it has been known that tubercidin strongly inhibits the proliferation of cells through interfering with numerous cellular processes that can result in significant cytotoxicity (Bergstrom et al., 1984). Therefore, many structure-activity relationship (SAR) studies have been conducted to overcome the latter. Previous studies have achieved successful outcomes with SAR studies, as some deazapurine nucleosides, such as NITD-008 (2′-C-ethynyltubercidin) (Yin et al., 2009) and remdesivir (GS-5734, the phosphoramidate prodrug of 1′-cyano-4-aza-7,9-dideazadenosine C-nucleoside analog) (Cho et al., 2012), were tested in nonclinical or clinical trials against various viral infections (Grein et al., 2020; Li and De Clercq, 2020; Yin et al., 2009). Recently, NITD-008 has been reported to demonstrate broad-spectrum antiviral activity against DENV1-4, ZIKV, YFV, WNV, and hepatitis C virus with lower cytotoxicity than tubercidin (Yin et al., 2009). According to previous reports, NITD-008 interferes with viral RdRp activity, leading to an inhibition of DENV2 replication in vitro and in vivo (Milligan et al., 2018; Yin et al., 2009). However, it exhibited significant toxicity when dosed orally in rats and dogs during the preclinical phases and could therefore not be developed further for clinical trials (Lim et al., 2015; Yin et al., 2009).

Other recent reports have shown that remdesivir may have an anti-Ebolavirus activity, and it has been reported to also have potent antiviral activities against Filoviridae (e.g. Marburg virus), Paramyxoviridae (e.g. Nipah virus and Hendra virus), Pneumoviridae (e.g. respiratory syncytial virus), Flaviviridae (e.g. Tick-borne encephalitis virus), and the Coronaviridae (e.g. HCoV-OC43, HCoV-229E, SARS-CoV, MERS-CoV, and SARS-CoV-2) (Agostini et al., 2018; Brown et al., 2019; Lo et al., 2017; Sheahan et al., 2017; Wang et al., 2020). Like NITD-008, remdesivir also inhibited viral RdRp activity, and the mechanism of action of remdesivir is considered to be due to delayed chain termination (Gordon et al., 2020; Tchesnokov et al., 2020). RdRp on the other hand is indispensable for the replication and transcription of the viral genome. Thus while there is a divergence of RdRp sequences between each viral family, the core structural features of RdRps are conserved (Venkataraman et al., 2018). These findings suggest that viral RdRp...
inhibitors, including nucleoside analogs, have the potential to serve as effective broad-spectrum antivirals.

HMTU is also a 7-deazaadenosine analog and C-5 substituted derivative of tubercidin. Although tubercidin and its C-5 substitutes have been reported to be cytotoxic adenosine analogs (Bergstrom et al., 1984), no strong cytotoxicity of HMTU was observed in our studies (Tables 1 and 4). Our study also revealed that HMTU inhibited both flavivirus and human coronavirus infections and dose dependently inhibited viral RNA replication, viral protein expression, and progeny virus production of HCoVs, SARS-CoV, and SARS-CoV-2 by functioning at a late stage of viral replication (Tables 2 and 3 and Figures 2, 3, and 4). HMTU was also found to potently inhibit both subgenomic and genomic viral RNA replication in coronavirus-infected cells and inhibited RNA extension after incorporation by viral RdRp. Our findings suggest that HMTU has the potential to be a lead compound for the development of a broad spectrum of anti-flavivirus and anti-coronavirus agents, including SARS-CoV-2, and that these could thus be further used for new drug discovery against SARS-CoV-2.

Figure 4. Time-of-addition assay for HMTU against SARS-CoV-2

(A and B) Viral RNA expression was quantified by qRT-PCR analysis. Caco-2 cells were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.1 for 1 h and treated with 1 μM of HMTU at the indicated time points (whole, entry, and post-entry). At 24 hpi, total RNA (A) and supernatants (B) were collected, and relative expressions of the nucleocapsid and RdRp genes were evaluated by qRT-PCR. Intracellular viral RNA levels were normalized to β-actin mRNA. Data represent mean values from two independent experiments, each carried out in triplicates. Error bars indicate SEM. Statistically significant differences were determined using a one-way ANOVA followed by Tukey’s multiple comparisons test; *p < 0.05, **p < 0.005, ***p < 0.0005, and ****p < 0.0001.

(C) Progeny virus titers were quantified by the TCID₅₀ assay. Caco-2 cells were infected with SARS-CoV-2 and treated with HMTU as described above. At 24 hpi, supernatants were collected, and dilutions were used to inoculate VeroE6/TMPRSS2 cells. Three days after inoculation, viral titers were determined by calculation of the TCID₅₀/mL. Data represent mean values from two independent experiments, each in triplicates. Error bars indicate SEM. Dotted line indicates the LOD.
Limitations of the study

Herein, we have using several approaches demonstrated the antiviral activities of tubercidin derivatives against both flaviviruses and human coronaviruses in vitro and have shown that HMTU had potent antiviral activity against both flaviviruses and coronaviruses, including SARS-CoV-2, and that this did not show cytotoxicity in several cell lines. However, in vivo antiviral activities and in vivo kinetics studies were not conducted in this study. Thus, further studies are needed to assess its safety, effectiveness, and potential clinical applications.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Cell lines
  - Viruses
- METHOD DETAILS
  - Generation ofTMPRSS2- and ACE2-expressing Cells
  - Compounds
  - Cytotoxicity assay
  - Indirect immunofluorescence assay
  - Time-of-addition assays

Figure 5. HMTU 5'-triphosphate impairs RNA extension by viral RdRp

(A) Analysis of chain termination activity of HMTU 5'-triphosphate (HMTU-TP) by the primer extension assay catalyzed by ZIKV RdRp. The RNA P/T used in this assay is indicated at the top (small black circles indicate the incorporation sites of ATP). ZIKV NS5 and RNA P/T were incubated with ATP analogs (500 μM ATP, 100 μM 3'-dATP, or serially diluted HMTU-TP), as indicated in each lane. Primer extension reactions were initiated by the addition of ATP, GTP, CTP, and UTP (100 μM each). The reactions were performed at 30°C for 2 h and stopped by the addition of quenching buffer. The products were resolved by denaturing PAGE.

(B) Relative band intensities of fluorescein-labeled RNA primers. Relative fluorescence intensities of each RNA primer (white arrowhead in Figure 5A) were normalized by the RNA sample without ATP or HMTU-TP (black bar, RNA only).
SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.103120.

ACKNOWLEDGMENTS

We thank Dr. Tomohiko Takasaki (Kanagawa Prefectural Institute of Public Health, Japan) for providing DENV1-4, Dr. Kouichi Morita (Nagasaki University, Japan) for providing SARS-CoV Hanoi strain, Dr. Masayuki Shimojima (National Institute of Infectious Diseases, Japan) for providing SARS-CoV-2 WK-S21 strain, and Dr. Hiroyuki Miyoshi (RIKEN BRC, Japan) for providing lentiviral vector plasmid CSII-CMV-MCS-ires2-Bsd. This work was supported by the Scientific Research on Innovative Areas and International Group from the MEXT/JSPS KAKENHI (JP16H06431, JP16H06429 and JP16K21723) and by the Japan Agency for Medical Research and Development (AMED) under Grant Numbers JP19fk0108111, JP20am0101093, JP20fk0108251, JP20k0108289, JP20wm0225003, JP20wm0225017, and JP21am0101093 and partially supported by the fund from the Atlantic Philanthropies director.

AUTHOR CONTRIBUTIONS

Project design, data analysis, and interpretation of the studies were performed by K.U., H.N., A.S., T.S., S.T., M.S., Y.O., H.K., W.W.H., H.S., A. Matsuda, and K.M.; generation of protein expression cells was performed by K.U. and M.S.; K.U., H.N., A.S., T.S., and H.K. performed antiviral assays; A. Murai, N.S.-T., N.M., A. Matsuda, and K.M. synthesized and analyzed the compounds; K.U. wrote the manuscript; W.W.H., H.S., A. Matsuda, and K.M. edited the manuscript. All authors read and approved the manuscript.

DECLARATION OF INTERESTS

The authors K.U., H.N., A.S., T.S., and T.S. are employees of Shionogi & Co., Ltd. M.S., Y.O., H.S., A. Matsuda, and K.M. have filed a patent on these compounds with Japanese Patent Office. The other authors declare no conflict of interests.

Received: April 13, 2021
Revised: July 21, 2021
Accepted: September 9, 2021
Published: October 22, 2021

REFERENCES

Agostini, M.L., Andres, E.L., Sims, A.C., Graham, R.L., Sheahan, T.P., Lu, X., Smith, E.C., Case, J.B., Feng, J.Y., Jordan, R., et al. (2020). Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9, 1–15. https://doi.org/10.1128/mBio.00221-18.

Bergstrom, D.E., Brattesani, A.J., Ogawa, M.K., Reddy, A., Schweickert, M.J., Balzarini, J., and De Clercq, E. (1984). Antiviral activity of c-5 substituted tuberculidin analogues. J. Med. Chem. 27, 285–292. https://doi.org/10.1021/jm00369a010.

Bergstrom, D.E., Brattesani, A.J., Ogawa, M.K., and Schweickert, M.J. (1981). Pyrimidine nucleoside antibiotic analogues Synthesis via organopalladium intermediates derived from 5-mercituribidin. J. Org. Chem. 46, 1423–1431. https://doi.org/10.1021/jo00320a038.

Brown, A.J., Won, J.J., Graham, R.L., Dinnon, K.H., Sims, A.C., Feng, J.Y., Chihle, T., Demond, M.R., Baric, R.S., and Sheahan, T.P. (2019). Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir. Res. 169, 104541. https://doi.org/10.1016/j.antiviral.2019.104541.

Cho, A., Saunders, O.L., Butler, T., Zhang, L., Xu, J., Vela, J.E., Feng, J.Y., Ray, A.S., and Kim, C.U. (2012). Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadencosine C'-nucleosides. Bioorg. Med. Chem. Lett. 22, 2705–2707. https://doi.org/10.1016/j.bmcl.2012.02.105.

Corman, V.M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D.K.W., Bleicker, T., Brunink, R., Schneider, J., Schmidt, M.L., et al. (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance 25, 1–8. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.

Cui, J., Li, F., and Shi, Z.L. (2019). Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181–192. https://doi.org/10.1038/s41579-018-0118-9.

De Clercq, E., Bernaerts, R., Bergstrom, D.E., Robins, M.J., Montgomery, J.A., and Holy, A. (1986). Antirhinovirus activity of purine nucleoside analogs. Antimicrob. Agents Chemother. 29, 482–487. https://doi.org/10.1128/AAC.29.3.482.

Emery, S.L., Erdman, D.D., Bowen, M.D., Newton, B.R., Winchell, J.M., Meyer, R.F., Tong, S., Cook, B.T., Holloway, B.P., McCaustland, K.A., et al. (2004). Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerg. Infect. Dis. 10, 311–316. https://doi.org/10.3201/eid1002.030759.

Eyer, L., Śmirdkowa, M., Nemcova, R., Necáš, J., Kastl, T., Palus, M., De Clercq, E., and Růžek, D. (2016). Structure-activity relationships of nucleoside analogues for inhibition of tick-borne encephalitis virus. Antivir. Res. 133, 119–129. https://doi.org/10.1016/j.antiviral.2016.07.018.

Gordon, C.J., Tchenskotov, E.P., Feng, J.Y., Porter, D.P., and Gotte, M. (2020). The antiviral compound remdesivir potently inhibits RNAdependent RNA polymerase from Middle
Easter respiratory syndrome coronavirus. J. Biol. Chem. 295, 4773–4779. https://doi.org/10.1074/jbc.A120.013056.

Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asuncion, E., Carfi, A., Feleti, T., Green, G., Green, M.L., Lescure, F.X., et al. (2020). Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med. 382, 2327–2336. https://doi.org/10.1056/NEJMc2007164.

Li, G., and De Clercq, E. (2020). Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 19, 149–150. https://doi.org/10.1038/s41573-019-0061-x.

Lim, S.P., Noble, C.G., and Shi, P.Y. (2015). The potential inhibitors of Zika virus RNA-dependent RNA polymerase by using nonradioactive polymerase assay. Antimicrob. Agents Chemother. 61, 1–15. https://doi.org/10.1128/AAC.02020-14.

Mackey, T.K., and Liang, B.A. (2012). Threats from recently emerged novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 11, 149–150. https://doi.org/10.1038/nrd3686.

Morita, K. (2004). Development and evaluation of a novel loop-mediated isothermal amplification method for rapid detection of severe acute respiratory syndrome coronavirus. J. Clin. Microbiol. 42, 1956–1961. https://doi.org/10.1128/JCM.42.5.1956-1961.2004.

Uematsu, T., and Suhadolcín, R.J. (1973). 5'-Hydroxymethylthiouracil. Synthesis, biological activity, and role in pyrimidine biosynthesis. J. Med. Chem. 16, 1405–1407. https://doi.org/10.1021/jm00270a021.

Venkataraman, S., Prasad, B.V.L.S., and Selvarajan, R. (2018). RNA dependent RNA polymerases: insights from structure, function and evolution. Viruses 10, 1–23. https://doi.org/10.3390/v10020076.

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., and Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271. https://doi.org/10.1038/s41422-020-0282-0.

Watanabe, S., and Ueda, T. (1983). Conversion of tubocurcin to toycamycin: some properties of tubocurcin derivatives (nucleosides and nucleotides 47). Nucleosides Nucleotides 2, 113–125. https://doi.org/10.1080/0732831830801253.

Yin, Z., Chen, Y.L., Schul, W., Wang, Q.Y., Gu, F., Duraiswamy, J., Kondreddi, R.R., Nyomratnarakat, P., Lakshminarayana, S.B., Goh, A., et al. (2009). An adenosine nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci. U S A 106, 20435–20439. https://doi.org/10.1073/pnas.0907010106.
### STAR METHODS

**KEY RESOURCES TABLE**

| Reagent or Resource | Source | Identifier |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Antibody            |        |            |
| Mouse monoclonal anti-coronavirus antibody | Merck Millipore | Cat# MAB9013; RRID: AB_95425 |
| Mouse monoclonal SARS-CoV / SARS-CoV-2 Spike antibody [1A9] | GeneTex | Cat# GTX632604; RRID: AB_2864418 |
| Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488 | Invitrogen | Cat# A32723; RRID: AB_2633275 |
| Hoechst 33342, Trihydrochloride, Trihydrate - FluoroPure Grade | Molecular Probes | Cat# H21492 |
| **Bacterial and virus strains** |        |            |
| Dengue virus 1 (D1/hu/PHL/10–07) | National Institute of Infectious Diseases | N/A |
| Dengue virus 2 (D2/hu/INDIA/09–74) | National Institute of Infectious Diseases | GenBank: LC367234 |
| Dengue virus 3 (D3/hu/Thailand/00–40) | National Institute of Infectious Diseases | N/A |
| Dengue virus 4 (D4/hu/Solomon/09–11) | National Institute of Infectious Diseases | N/A |
| Zika virus (MR766) | National Institute of Infectious Diseases | GenBank: LC002520 |
| Yellow fever virus (17D–204) | Nagasaki University | N/A |
| Japanese encephalitis virus (Beijing–1) | Hokkaido University | N/A |
| West Nile virus (NY99) | Hokkaido University | N/A |
| Human coronavirus OC43 | ATCC | Cat# VR-1558 |
| Human coronavirus 229E | ATCC | Cat# VR-740 |
| SARS-CoV (Hanoi) | Nagasaki University (Thai et al., 2004) | N/A |
| SARS-CoV-2 (JP/TY/WK-521) | National Institute of Infectious Diseases (Matsuyama et al., 2020) | GISAID: EPI_ISL_408667 |
| **Chemicals, peptides, and recombinant proteins** |        |            |
| 5-hydroxymethyltubercidin (HMTU) | This paper | N/A |
| HMTU 5’-triphosphate (HMTU-TP) | This paper | N/A |
| Ribavirin | FUJIFILM Wako | Cat# 188-02333 |
| Favipiravir | PharmaBlock Sciences | N/A |
| Remdesivir (GS-5734) | MedChemExpress | Cat# HY-104077 |
| ATP solution | Thermo Fisher Scientific | Cat# R0441 |
| 3'-Deoxyadenosine-5’-Triphosphate (3’-dATP) | TriLink BioTechnologies | Cat# N-3001 |
| Recombinant ZIKV NS5 protein | Sino Biological | Cat# 40546-V08B |
| RNasin Ribonuclease inhibitor | Promega | Cat# N2115 |
| **Critical commercial assays** |        |            |
| PureLink RNA Mini Kit | Invitrogen | Cat# 12183025 |
| PureLink Pro 96 Viral RNA/DNA Kit | Invitrogen | Cat# 12280096A |
| THUNDERBIRD Probe One-step qRT-PCR kit | TOYOBO | Cat# QRZ-101 |
| Novex TBE-Urea Gels, 15% | Invitrogen | Cat# EC68852BOX |
| **Experimental models: Cell lines** |        |            |
| Hamster: BHK-21 cells | ATCC | CCL-10 |
| African green monkey: Vero E6 cells | ATCC | CRL-1586 |
| Human: MRCS cells | ATCC | CCL-171 |
| Human: 293T cells | RIKEN BRC | RCB2202 |

(Continued on next page)
RESOURCES AVAILABILITY

**Lead contact**
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Akihiko Sato: akihiko.sato@shionogi.co.jp.

**Materials availability**
This study did not generate new unique materials.

**Data and code availability**
This study did not generate and analyze any datasets or code. All data are included in the article and supplemental information and any additional information will be available from the lead contact upon request.

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

**Cell lines**
BHK-21 (ATCC), 293T (RIKEN BRC), VeroE6 (ATCC), Huh7 (RIKEN BRC), and A549 (RIKEN BRC) cells were maintained in high-glucose Dulbecco’s modified Eagle’s medium (Gibco; Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS, Gibco) and penicillin–streptomycin (P/S, Wako) at 37°C. MRC5 (ATCC) and Caco-2 cells (RIKEN BRC) were also maintained in Minimum Essential Medium GlutaMAX Supplement (Gibco) supplemented with 10% FBS, nonessential amino acids (Wako), sodium pyruvate (Wako), and P/S at 37°C.

**Viruses**
DENV1 (D1/hu/PHL/10-07), DENV2 (D2/hu/INDIA/09-74), DENV3 (D3/hu/Thailand/00-40), DENV4 (D4/hu/Solomon/09-11), ZIKV (MR766), YFV (17D-204), JEV (Beijing-1), and WNV (NY99) were propagated as described in previous reports (Nobori et al., 2018).
Human coronavirus strain OC43 (HCoV-OC43) and 229E (HCoV-229E) were purchased from ATCC (VR-1558 and VR-740, respectively) and amplified on MRC5 cells. SARS-CoV strain Hanoi was kindly provided by Dr. Kouichi Morita (Nagasaki University, Nagasaki, Japan) and was amplified in VeroE6 cells (Thai et al., 2004), whereas the SARS-CoV-2 strain JPN/TY/WK–521, a clinical isolate from a patient with COVID-19 (Matsuyama et al., 2020) was kindly provided by Dr. Masayuki Shimojima (National Institute of Infectious Diseases, Tokyo, Japan) and amplified on VeroE6/TMPRSS2 cells. WNV, SARS-CoV, and SARS-CoV-2 were propagated in a biosafety level-3 (BSL-3).

Virus infectious titers were also measured by inoculating respective cells with serial dilutions of the virus; while the cytopathic effect (CPE) was scored to calculate the TCID50/mL.

**METHOD DETAILS**

**Generation of TMPRSS2- and ACE2-expressing Cells**

VeroE6 and A549 cells stably expressing human TMPRSS2 (VeroE6/TMPRSS2 and A549/TMPRSS2) were generated by lentiviral transduction with CSII-CMV-TMPRSS2-IRES2-Bsd (Sasaki et al., 2021) and blastidin-based selection. MRC5 cells stably expressing human ACE2 (MRC5/ACE2) were also generated by lentiviral transduction as described in previous report (Uemura et al., 2021). For the lentiviral vector preparation, 293T cells were co-transfected with the aforementioned lentiviral vector plasmid and Lentiviral High Titer Packaging Mix (Takara Bio, Shiga, Japan).

**Compounds**

All tubercidin derivatives, including 5-hydroxymethyltubercidin (HMTU) (Bergstrom et al., 1981; Uematsu and Suhadolnik, 1973; Watanabe and Ueda, 1983), were synthesized at the Faculty of Pharmaceutical Sciences, Hokkaido University and their chemical identity and purity were determined by high-performance liquid chromatography and mass spectrometry analysis. Ribavirin, Favipiravir, and GS-5734 (Remdesivir) were purchased from FUJIFILM Wako Pure Chemical Corporation, PharmaBlock Sciences, Inc. and MedChemExpress, respectively, after which all compounds were solubilized in 100% dimethyl sulfoxide (DMSO; Sigma-Aldrich) for in vitro studies.

For the RNA extension assays, HMTU 5’-triphosphate (HMTU-TP) was synthesized at the Graduate School of Pharmaceutical Sciences, Tokushima University and their chemical identity and purity were determined by nuclear magnetic resonance and mass spectrometry analysis (Figure S1 and Data S1). HMTU-TP was solubilized in nuclease-free water. ATP and 3’-dATP were purchased from Thermo Fisher Scientific and TriLink BioTechnologies.

**Cytopathic effect-based antiviral and cytotoxicity assays**

The MTT (3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide) and resazurin reduction assays were carried out as previously described (Nobori et al., 2018; Sanaki et al., 2019). These were performed to calculate cell viability following viral induced CPE or cytotoxicity. Assay conditions for flaviviruses are as described in Table 2.

For human coronavirus CPE-based antiviral assay, MRC5 cells were seeded onto 96-well plates with serially diluted compounds in each well. The cells were infected with HCoV-OC43 at an MOI of 0.1 or HCoV-229E at a multiplicity of infection (MOI) of 0.05 or 0.01, respectively. After 72 h at 37°C, the resazurin reduction assay was conducted to calculate cell viability.

The EC50 value was defined in GraphPad Prism version 8.4.2 (GraphPad Software) with a variable slope (four parameters). Noninfected cells were used as a control for 100% inhibition, whereas for infected cells, DMSO alone was used as a control for 0% inhibition. The CC50 value for each cell line was also measured using the same method. Cell-free samples were used as 100% cytotoxicity control and DMSO-treated cells were used as 0% cytotoxicity control.

**Quantification of viral RNA with real-time quantitative reverse transcription PCR (qRT–PCR)**

For HCoV-OC43 and HCoV-229E, Huh7 cells were seeded the previous day and infected with HCoV-OC43 at an MOI of 0.1 or HCoV-229E at an MOI of 0.05 containing the serially diluted compound for 1 h. For SARS-CoV and SARS-CoV-2, Caco-2 cells were seeded the previous day and also infected with these viruses at an
MOI of 0.1 containing the serially diluted compound for 1 h. After incubation, the unbound virus was removed and new medium containing the serially diluted compound was added. At 48 h post-infection (hpi), total RNA was isolated with PureLink RNA Mini Kit (Invitrogen; Thermo Fischer Scientific).

For rescreening of the nine tubercidin derivatives, Caco-2 cells were seeded the previous day and infected with SARS-CoV-2 at an MOI of 0.1 containing the serially diluted compound for 48 h. After incubation, the culture supernatants were collected, after which viral RNA was isolated by PureLink Pro 96 Viral RNA/DNA Kit (Invitrogen; Thermo Fischer Scientific).

Viral RNA from all samples was quantified using real-time RT–PCR analysis with THUNDERBIRD Probe One-step qRT–PCR kit (TOYOBO) and QuantStudio 7 Flex Real-Time PCR system (Applied Biosystems; Thermo Fischer Scientific). The primers and probe sequences (Integrated DNA Technologies, IDT) targeting the nucleocapsid gene to detect subgenomic viral RNA and the ORF1b or RdRp gene to detect viral genomic RNA were designed in previous reports (Brown et al., 2019; Corman et al., 2020; Emery et al., 2004; Loens et al., 2012), with the primers and probe for ACTB (Hs01060665_g1, Applied Biosystems) transcripts used as internal controls.

**Virus replication assay (TCID50 Assay)**

For testing samples were collected using the same method as in the qRT–PCR assays. At 48 hpi, culture supernatants were also collected, after which, serial dilutions were prepared. Dilutions were used to inoculate MRC5 cells for HCoVs, VeroE6 cells for SARS-CoV, and VeroE6/TMPRSS2 cells for SARS-CoV-2, and at 72 hpi, viral titers were determined by calculating the TCID50/mL.

**Indirect immunofluorescence assay**

For HCoV-OC43, A549/TMPRSS2 cells were seeded on the day before viral infection, after which, cells were infected with HCoV-OC43 at an MOI of 1 containing the serially diluted compound. For SARS-CoV and SARS-CoV-2, MRC5/ACE2 cells were seeded on the day before viral infection, after which, cells were infected with SARS-CoV at an MOI of 0.1 or SARS-CoV-2 at an MOI of 0.05 containing the serially diluted compound. At 48 hpi, cells were fixed with 4% paraformaldehyde (Nacalai tesque) or the Masked Form A (Japan Tanner Co.), permeabilized with 0.5% Triton X-100 in PBS or ice-cold methanol. Cells were then stained with the anti-coronavirus antibody (MAB9013, Merck Millipore), anti-SARS-CoV Spike antibody (1A9; GTX632604, GeneTex) and Alexa Fluor Plus 488-conjugated anti-mouse IgG antibody (Invitrogen). Cell nuclei were counterstained with Hoechst 33342 (Molecular Probes; Thermo Fischer Scientific). Cells were then evaluated using fluorescence microscopy (IX73, Olympus). Images were processed with cellSens Standard 1.16 (Olympus).

**Time-of-addition assays**

The time-of-addition assay was performed according to previous reports (Ohashi et al., 2021; Wang et al., 2020). Briefly, Caco-2 cells were seeded on the day before SARS-CoV-2 infection (MOI of 0.1) and compound treatment. One micromolar HMTU or DMSO was then added at the indicated time points (Whole, Entry, and Post-entry). For “Whole” treatment, the cells were incubated with both the compound and virus for 1 h. After incubation, unbound viruses were removed, and the cells were cultured with HMTU-containing medium for 2 h to allow viral entry. At 3 hpi, culture supernatants were replaced with new HMTU-containing media and maintained until the end of the experiment. For “Entry” treatment, the cells were incubated as described above, and at 3 hpi, HMTU-containing media were replaced with fresh culture media and maintained until the end of the experiments. For “Post-entry” treatment, HMTU was added to the virus-infected cells at 3 hpi and maintained until the end of the experiment. At 24 hpi, total RNA was isolated, and viral RNA was quantified using qRT–PCR analysis as described above. Supernatants were collected, after which serial dilutions of these supernatants were used to inoculate a monolayer of the VeroE6/TMPRSS2 cells. Three days after inoculation, the CPE was scored, and TCID50/mL was calculated to measure viral titers.

**Primer and template annealing**

To generate RNA primer-template complexes (RNA P/T), 0.5 μM fluorescently labeled RNA primer and 2 μM unlabeled RNA template were mixed in 50 mM NaCl, incubated at 95°C for 10 min, and then slowly cooled down to room temperature. The annealed RNA P/T was stored at -30°C before use in the primer extension assay.
Primer extension polymerase activity assay
The primer extension assay was performed according to a previous report (Lu et al., 2017). For analysis of the competitive inhibition ability of HMTU-TP, 200 nM of recombinant ZIKV NS5 (Sino Biological) and 50 nM RNA P/T were incubated 30°C for 15 min in reaction buffer [10 mM Tris-HCl (pH 7.5), 10 mM DTT, 5 mM MgCl2, 5% glycerol, 0.05% Triton-X 100, and 0.02 U/μL RNasein (Promega)], and then ATP analogs [500 μM ATP (Thermo Fischer Scientific), 100 μM 3’-dATP (TriLink), or serially diluted HMTU-TP (0.025, 0.1, 0.4 or 1.6 mM)] were added and incubated at 30°C for 10 min. Primer extension reactions were initiated by the addition of ATP, GTP, CTP and UTP (100 μM each). The reactions were performed 30°C for 2 h and stopped by the addition of quenching buffer (7M Urea, 1X TBE buffer, and 50 mM EDTA). The quenched samples were denatured at 95°C for 5 min, and the primer extension products were separated on a 15% denaturing polyacrylamide gel (Invitrogen). After electrophoresis, the gels were scanned using an Amersham ImageQuant 800 Fluor system (Cytiva). The band intensities were analyzed by ImageQuant TL version 8.2.0 (Cytiva).

QUANTIFICATION AND STATISTICAL ANALYSIS
All bar graphs in this study were presented as mean ± SEM. One-way ANOVA followed by Dunnett’s or Tukey’s multiple comparisons test was also performed to determine the statistical significance using GraphPad Prism version 8.4.2. A p value of < 0.05 was considered statistically significant; * p < 0.05, ** p < 0.005, *** p < 0.0005, and **** p < 0.0001.